{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T02:09:48Z","timestamp":1789524588459,"version":"build-2803163510"},"reference-count":39,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Allopurinol is known to cause severe cutaneous adverse drug reactions (SCAR) in Malaysia. However, the incidence of allopurinol\u2010induced SCAR is unknown. Therefore, we aimed to determine the incidence of allopurinol\u2010induced SCAR in Malaysia over 5 years from 2015 to 2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This retrospective analysis was done in collaboration with the National Pharmaceutical Regulatory Agency (NPRA). All allopurinol\u2010induced adverse drug reaction cases reported to NPRA from 2015 to 2019 were extracted. Allopurinol\u2010induced SCAR cases were identified and the incidence over the 5 years was calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Incidence of allopurinol\u2010induced SCAR averaged at 2.5 cases per 1000 new users over the 5\u2010year period, with a reducing trend from 3.2 per 1000 new users in 2015 to 2.25 per 1000 in 2019; despite the increasing number of adverse drug reaction cases being reported over the years. Stevens\u2013Johnson syndrome was the commonest form of allopurinol\u2010induced SCAR reported, at 143 cases (46.8% of total SCAR reported). Among Malaysia's 3 main ethnicities, the Chinese had the highest percentages of allopurinol\u2010induced SCAR when compared to the Bumiputera and Indians (3.18 \u00d7 10<jats:sup>\u22124<\/jats:sup>%).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The estimated incidence of allopurinol\u2010induced SCAR in Malaysia from 2015 to 2019 was 2.5 cases per 1000 new users. This figure is consistent with the incidence reported in other Asian countries, namely Taiwan and Thailand.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.15327","type":"journal-article","created":{"date-parts":[[2022,3,23]],"date-time":"2022-03-23T05:58:06Z","timestamp":1648015086000},"page":"3782-3788","source":"Crossref","is-referenced-by-count":9,"title":["Incidence of allopurinol\u2010induced severe cutaneous adverse drug reaction in Malaysia"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3074-9114","authenticated-orcid":false,"given":"Wei Leik","family":"Ng","sequence":"first","affiliation":[{"name":"Department of Primary Care Medicine, Faculty of Medicine University of Malaya  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kheng Seang","family":"Lim","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine, Faculty of Medicine University of Malaya  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vidhya","family":"Hariraj","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Section, Centre of Compliance and Quality Control National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health  Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sing Chet","family":"Lee","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Section, Centre of Compliance and Quality Control National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health  Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee Kee","family":"Wo","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Section, Centre of Compliance and Quality Control National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health  Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azuana","family":"Ramli","sequence":"additional","affiliation":[{"name":"Pharmacovigilance Section, Centre of Compliance and Quality Control National Pharmaceutical Regulatory Agency (NPRA), Ministry of Health  Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline Siew Mei","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Primary Care Medicine, Faculty of Medicine University of Malaya  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si Lei","family":"Fong","sequence":"additional","affiliation":[{"name":"Division of Neurology, Department of Medicine, Faculty of Medicine University of Malaya  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Ran","family":"Lim","sequence":"additional","affiliation":[{"name":"Department of Primary Care Medicine, Faculty of Medicine University of Malaya  Kuala Lumpur Malaysia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002281\u2010200205000\u201000015"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24180"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp030733"},{"key":"e_1_2_11_5_1","unstructured":"LeeCK A.M.A. LeeYY ChangCC BabaR Allopurinol Induced Adverse Cutaneous Drug Reactions (ACDRs): A Review of MADRAC (Malaysian Adverse Drug Reaction Advisory Committee) Report from 2000\u20132009.2012: Malaysia."},{"issue":"2","key":"e_1_2_11_6_1","first-page":"73","article-title":"A 10\u2010years retrospective study on Severe Cutaneous Adverse Reactions (SCARs) in a tertiary hospital in Penang, Malaysia","volume":"73","author":"Loo CH","year":"2018","journal-title":"Med J Malaysia"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20104632.2010.04481.x"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409500102"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.11.1617"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471\u20102350\u201012\u2010118"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4848"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.3536"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094294"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018\u2010200831080\u201000002"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21817"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr060"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010013\u20100084\u20100"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441\u2010020\u201000245\u2010w"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378\u20106323.102367"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0000000000000408"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gku1166"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2016.06.022"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2019.09.005"},{"key":"e_1_2_11_24_1","first-page":"203","article-title":"Severe Cutaneous Adverse Reactions to Drugs (SCAR): Definitions, diagnostic criteria, genetic predisposition","volume":"27","author":"Roujeau JC","year":"2009","journal-title":"Dermatol Sinica"},{"key":"e_1_2_11_25_1","unstructured":"WHO:Tools and toolkits\/ATC\u2010DDD Toolkit\/DDD Indicators.2020; Available from:https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/indicators"},{"key":"e_1_2_11_26_1","volume-title":"2020, Pharmaceutical Services Programme","author":"Malaysian Statistics on Medicines","year":"2015"},{"key":"e_1_2_11_27_1","unstructured":"Department of Statistics M.Current population estimates Malaysia.2021; Available from:https:\/\/www.dosm.gov.my\/v1\/index.php?r=home\/index&menu_id=OWNEc3U1QXJCQ1BuZVg0ZjcxTzlmUT09"},{"key":"e_1_2_11_28_1","unstructured":"Methodology W.C.C.f.D.S. WHO Collaborating Centre for Drug Statistic Methodology. ATC\/DDD Index for allopurinol2020."},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2020.09.011"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2020.1743262"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00186"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.469"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.abd.2019.01.007"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.91"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez476"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801\u2010019\u201000174\u20107"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5033"},{"key":"e_1_2_11_38_1","unstructured":"Guidelines for Preparing Core Clinical Safety Information on Drugs: Report of CIOMS Working Groups III.1995: Geneva."},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264\u2010012\u20100014\u20106"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14747"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15327","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15327","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T05:00:37Z","timestamp":1692680437000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/bcp.15327"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15327","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]}}}